ACADIA PHARMACEUTICALS INC. (ACAD) Profit Breakdown
- 2026-06-30: Reportable Segment, Aggregation before Other Operating $295.17M.
- 2025-06-30: Reportable Segment, Aggregation before Other Operating $256.18M.
Complete filed revenue-to-profit bridge showing gross profit, operating income, pre-tax income and net income.
- Available history
- 2009-12-31 to 2026-06-30
- Data captured
Profit by product
Gross margin: each quarter (3 month)
| Quarter end | Reportable Segment, Aggregation before Other Operating |
|---|---|
| 2026-06-30 | $295.17M derived |
| 2025-06-30 | $256.18M derived |
Net Income (Loss) Attributable to Parent: each quarter (3 month)
| Quarter end | Reportable Segment, Aggregation before Other Operating |
|---|---|
| 2026-06-30 | $31.50M |
| 2025-06-30 | $26.67M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |